~ Positive Enrollment Progress and Safety Data ~

~ FDA Attention Establishes Momentum in the Pain Treatment Space ~

~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~

~ FDA Breakthrough Therapy designation received for PF614-MPAR ~
~ PF614-MPAR second clinical trial initiated ~
~ Lead clinical candidate identified for OUD program ~
~ PF614 Phase 3 trial poised to commence 1H 2025 ~

~ Supply Chain Now Fully Secure for PF614-MPAR ~

~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~

~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~

~ Expects Early Interim Data in 1Q 2025 ~